Stockreport

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis...

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF -STAT3 inhibition does not impair the interferon-mediated antiviral defense or hematopoietic growth factor signaling, as seen with JAK/TYK2 inhibitors SAN DIEGO, Nov. [Read more]